Titre du document / Document title
Aplicaciones de anticuerpos monoclonales y productos de biotecnología en el tratamiento de las enfermedades inflamatorias crÓnicas = Applications of monoclonal antibodies and biotechnology products in the treatment of chronic inflammatory diseases
Auteur(s) / Author(s)MARENCO DE LA FUENTE J. L.
Résumé / Abstract
In recent years we have noticed the arrival of biological drugs for the treatment of rheumatoid arthritis (RA), Crohn's disease (CD), psoriasis, and other chronic inflammatory diseases. Those drugs are produced with biotechnology methods and are defined as biologicals because of they work on the immune system. Different cellular groups and inflammation mediators participate in the inflammatory process, all of them susceptible of a therapeutic approach; they are so-called biological targets. Inhibition of TNF and interleukina 1 (IL-1) has proven effective for the control of inflammation in diseases as RA or CD. At present we have two types of inhibitors of TNF, specific monoclonal antibodies (infliximab, adalimumab) and cellular receptors (etanercept) and an IL-1 inhibitor (anakinra). The use of TNF inhibitors has given rise to a substantial change in the treatment of RA and CD because of its effectiveness. Together with this beneficial effect, an increase of infections (some of them severe) has occurred, especially tuberculosis. Other side effects that can be considered infrequent include demyelinization, herat failure, blood dyscrasias and lymphomas, which means that a thorough knowledge of these drugs is necessary for their use. Other potential biological drugs still in investigational phase are mentioned.
Revue / Journal TitleRevista clinica espanola
Source / Source
2005, vol. 205, no
3, pp. 127-136 [10 page(s) (article)]
Langue / Language
Editeur / Publisher
Elsevier, Barcelone, ESPAGNE
Localisation / Location
INIST-CNRS, Cote INIST : 6447, 35400012598125.0080
Nº notice refdoc (ud4) : 16717324